Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

Vertex's core business continues to drive strong financial results. The biotech has an exciting late-stage pipeline that could make significant progress in the next few years. It's a good idea to go ...

BofA lowered the firm’s price target on Vertex (VERX) to $24 from $34 and keeps a Neutral rating on the shares following a “disappointing” Q4 outlook. With the implied growth rate in Q4 of 9% toward ...

Vertex Pharmaceuticals (VRTX) is gaining attention as new clinical data for its kidney disease therapy, povetacicept, shows encouraging results. The company’s portfolio is also benefiting from steady ...

Vertex has begun a full-court press for Journavx, enlisting NBA All-Star Jayson Tatum to discuss his use of the new non-opioid painkiller while recovering from a serious injury. Tatum ruptured his ...

Journal Editorial Report: The Fed Chief signals rate cuts are coming. As we saw during the Covid pandemic, lab-created experiments can wreak havoc when they escape their confines. Once released, they ...

Ever wonder what you'd get if you mashed up Minecraft and No Man's Sky? The answer is Cubic Odyssey and now this adventure is even better when shared, thanks to a new patch which gives its co-op ...

The U.S. Air Force has awarded Cubic Defense Applications a potential $399 million follow-on firm-fixed-price, indefinite-delivery/indefinite-quantity contract for P5 ...

— Povetacicept (pove) IgAN Phase 3 interim analysis (IA) cohort fully enrolled and zimislecel Phase 3 program to complete dosing this quarter, setting up potential filings in 2026; inaxaplin Phase 3 ...